Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
7 | 4 | CARDIAC & CARDIOVASCULAR SYSTEM//PERIPHERAL VASCULAR DISEASES//CARDIOL | 1572904 |
18 | 3 | HEMATOLOGY//THROMBOSIS AND HAEMOSTASIS//THROMBOSIS RESEARCH | 124610 |
922 | 2 | WARFARIN//DABIGATRAN//RIVAROXABAN | 11329 |
875 | 1 | DABIGATRAN//RIVAROXABAN//APIXABAN | 3036 |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | DABIGATRAN | authKW | 4781656 | 21% | 73% | 628 |
2 | RIVAROXABAN | authKW | 4746864 | 22% | 70% | 655 |
3 | APIXABAN | authKW | 3228457 | 14% | 75% | 417 |
4 | EDOXABAN | authKW | 1581775 | 6% | 82% | 186 |
5 | DABIGATRAN ETEXILATE | authKW | 957288 | 4% | 82% | 112 |
6 | FACTOR XA INHIBITOR | authKW | 955408 | 6% | 47% | 195 |
7 | DIRECT ORAL ANTICOAGULANTS | authKW | 873269 | 4% | 70% | 121 |
8 | ANTICOAGULANTS | authKW | 602063 | 16% | 12% | 496 |
9 | IDARUCIZUMAB | authKW | 488032 | 2% | 98% | 48 |
10 | NEW ORAL ANTICOAGULANTS | authKW | 463437 | 3% | 53% | 84 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Peripheral Vascular Diseases | 23990 | 26% | 0% | 797 |
2 | Hematology | 20530 | 25% | 0% | 768 |
3 | Cardiac & Cardiovascular System | 7466 | 20% | 0% | 615 |
4 | Pharmacology & Pharmacy | 2684 | 19% | 0% | 584 |
5 | Medicine, General & Internal | 2402 | 14% | 0% | 433 |
6 | Emergency Medicine | 605 | 2% | 0% | 63 |
7 | Anesthesiology | 223 | 2% | 0% | 60 |
8 | Medical Laboratory Technology | 205 | 2% | 0% | 49 |
9 | Clinical Neurology | 159 | 5% | 0% | 145 |
10 | Critical Care Medicine | 127 | 2% | 0% | 49 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | GLOBAL CLIN DEV MED AFFAIRS | 66424 | 0% | 80% | 8 |
2 | PHARMACOMETRY | 62275 | 0% | 100% | 6 |
3 | UPPSALA CLIN | 49736 | 2% | 9% | 55 |
4 | CITY HOSP | 46796 | 3% | 5% | 85 |
5 | NTHC | 43235 | 0% | 42% | 10 |
6 | THROMBOSIS ATHEROSCLEROSIS | 41810 | 1% | 16% | 25 |
7 | AALBORG THROMBOSIS UNIT | 41301 | 1% | 15% | 27 |
8 | INT SURG THROMBOSIS FORUM | 37066 | 0% | 71% | 5 |
9 | GRP RECH THROMBOSE | 33951 | 0% | 27% | 12 |
10 | CLIN CARDIOL ANGIOL 1 | 31138 | 0% | 100% | 3 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 48229 | 3% | 5% | 95 |
2 | THROMBOSIS AND HAEMOSTASIS | 26524 | 5% | 2% | 161 |
3 | JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 25458 | 3% | 2% | 100 |
4 | THROMBOSIS RESEARCH | 14059 | 4% | 1% | 119 |
5 | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 12379 | 1% | 5% | 23 |
6 | CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | 7402 | 1% | 2% | 35 |
7 | HAMOSTASEOLOGIE | 6574 | 1% | 4% | 17 |
8 | SEMINARS IN THROMBOSIS AND HEMOSTASIS | 4625 | 1% | 1% | 35 |
9 | JOURNAL OF STROKE & CEREBROVASCULAR DISEASES | 3936 | 1% | 1% | 32 |
10 | INTERNAL AND EMERGENCY MEDICINE | 3778 | 1% | 2% | 18 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | DABIGATRAN | 4781656 | 21% | 73% | 628 | Search DABIGATRAN | Search DABIGATRAN |
2 | RIVAROXABAN | 4746864 | 22% | 70% | 655 | Search RIVAROXABAN | Search RIVAROXABAN |
3 | APIXABAN | 3228457 | 14% | 75% | 417 | Search APIXABAN | Search APIXABAN |
4 | EDOXABAN | 1581775 | 6% | 82% | 186 | Search EDOXABAN | Search EDOXABAN |
5 | DABIGATRAN ETEXILATE | 957288 | 4% | 82% | 112 | Search DABIGATRAN+ETEXILATE | Search DABIGATRAN+ETEXILATE |
6 | FACTOR XA INHIBITOR | 955408 | 6% | 47% | 195 | Search FACTOR+XA+INHIBITOR | Search FACTOR+XA+INHIBITOR |
7 | DIRECT ORAL ANTICOAGULANTS | 873269 | 4% | 70% | 121 | Search DIRECT+ORAL+ANTICOAGULANTS | Search DIRECT+ORAL+ANTICOAGULANTS |
8 | ANTICOAGULANTS | 602063 | 16% | 12% | 496 | Search ANTICOAGULANTS | Search ANTICOAGULANTS |
9 | IDARUCIZUMAB | 488032 | 2% | 98% | 48 | Search IDARUCIZUMAB | Search IDARUCIZUMAB |
10 | NEW ORAL ANTICOAGULANTS | 463437 | 3% | 53% | 84 | Search NEW+ORAL+ANTICOAGULANTS | Search NEW+ORAL+ANTICOAGULANTS |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |